Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT2B | Q92831 | 15/20 | 1.00 |
| ▸ | EP300 | Q09472 | 2/20 | 0.70 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.70 |
| ▸ | KAT2A | Q92830 | 2/20 | 0.70 |
| ▸ | MMP10 | P09238 | 2/20 | 0.69 |
| ▸ | G6PD | P11413 | 1/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29798990 | 1.00 | KAT2B (1.00) | KAT2BEP300CREBBPKAT2AMMP10 | |
| SCHEMBL29798968 | 0.83 | KAT2B (1.00) | KAT2BEP300CREBBPKAT2AMMP10 | |
| SCHEMBL26964521 | 0.83 | KAT2B (1.00) | KAT2BEP300CREBBPKAT2AMMP10 | |
| SCHEMBL1902882 | 0.83 | KAT2B (0.70) | KAT2BEP300CREBBPKAT2AMMP10 | |
| SCHEMBL29530268 | 0.83 | KAT2B (0.70) | KAT2BEP300CREBBPKAT2AMMP10 | |
| SCHEMBL29711802 | 0.82 | KAT2B (1.00) | KAT2BEP300CREBBPKAT2AMMP10 | |
| SCHEMBL20771520 | 0.82 | KAT2B (1.00) | KAT2BEP300CREBBPKAT2AMMP10 | |
| SCHEMBL20350785 | 0.82 | KAT2B (1.00) | KAT2BEP300CREBBPKAT2AMMP10 | |
| SCHEMBL17515280 | 0.79 | KAT2B (0.76) | KAT2BEP300CREBBPKAT2AMMP10 | |
| SCHEMBL1897990 | 0.76 | G6PD (1.00) | KAT2BEP300KAT2AG6PDPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018180-A1 | OLIGONUCLEOTIDE PRODUCTION METHOD | AJINOMOTO CO., INC. (JP) | 2024-01-18 | — | — | US | claimed |
| EP-4293035-A1 | OLIGONUCLEOTIDE PRODUCTION METHOD | AJINOMOTO CO., INC. (JP) | 2023-12-20 | — | — | EP | claimed |
| US-20240018180-A1 | OLIGONUCLEOTIDE PRODUCTION METHOD | AJINOMOTO CO., INC. (JP) | 2024-01-18 | — | — | US | disclosed |
| US-20240018180-A1 | OLIGONUCLEOTIDE PRODUCTION METHOD | AJINOMOTO CO., INC. (JP) | 2024-01-18 | — | — | US | disclosed |
| EP-4293035-A1 | OLIGONUCLEOTIDE PRODUCTION METHOD | AJINOMOTO CO., INC. (JP) | 2023-12-20 | — | — | EP | disclosed |
| WO-2022172994-A1 | OLIGONUCLEOTIDE PRODUCTION METHOD | 味の素株式会社 | 2022-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018180-A1 | OLIGONUCLEOTIDE PRODUCTION METHOD | RNGTT, NOX4, POLRMT | KAT2B 1902/4885EP300 3591/4885CREBBP 1940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.